Thermo Fisher Scientific sells microbiology business to Astorg for $1.075 billion
Updated
Updated · The Wall Street Journal · Apr 27
Thermo Fisher Scientific sells microbiology business to Astorg for $1.075 billion
16 articles · Updated · The Wall Street Journal · Apr 27
The microbiology unit generated $645 million in revenue last year and the deal includes cash plus a $50 million seller note.
Thermo Fisher expects the sale to reduce adjusted per-share earnings by 15 cents in its first full year, with completion anticipated in the second half of 2026.
Astorg, a European private-equity firm managing over $28 billion in assets, recently sold Clario Holdings to Thermo Fisher for nearly $8.9 billion in March.
This deal cuts Thermo Fisher's earnings. What major acquisition will the nearly $1.1B in capital fund next?
Is Thermo Fisher's $1.075B sale a strategic masterstroke or the loss of a future diagnostics powerhouse?
How will this new company compete when its former parent, Thermo Fisher, remains a major market player?
With antimicrobial resistance surging, will private equity ownership accelerate or stifle critical diagnostic innovations?
How will 2,400 employees fare as their business shifts from a public giant to a private equity platform?